Unlocking the future of healthcare:

The EU Health Technology Assessment (HTA) journey

As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment. At Cencora, we help companies at all stages of the EU HTA journey, from early evidence to post-JCA implementation at the national level. 

Our EU HTA Center of Excellence brings together expert domain leaders with deep knowledge of the intricacies of this complex initiative. Unveiling the path forward, our experts offer unparalleled insights into the current status of EU HTA, shed light on the uncertainties that lie ahead, and equip you with solutions to help you navigate this transformative landscape.

EU HTA Center of Excellence

500+
HTA submissions delivered across Europe over the last 5 years
250+
HTA, RWE, and market access consultants across Europe

One expert partner, from early evidence advice to post-JCA implementation

Cencora helps deliver an optimized JCA by providing specialist capabilities, robust capacity, and strategic partnership.

Readiness

  • Affiliate activation and engagement models
  • Education and awareness initiatives
  • Organisational audit and change management

Strategy

  • Joint scientific consultation (JSC)
  • Early evidence planning
  • PICO simulation
  • Core HTA strategy and EU launch planning

Implementation

  • Evidence review 
  • Statistical analysis

  • JCA submission writing
  • Post-JCA implementation support

Explore our latest insights

Navigating the bumpy road ahead: stakeholder perspectives on EU HTAR

The Evidence Base
Cencora

Article

Not long until the Joint Clinical Assessment begins: Will PICO anxiety become a reality?

HTA Quarterly
Cencora

Article

Latest guidelines for statistical analysis in EU HTA 

Michael Hennig, PhD
Cencora

Meet Ruairi O’Donnell, EU HTA Lead at Cencora

A 20-year veteran of the global market access and HEOR consulting services sector, Ruairi has held numerous leadership positions in leading global consulting organizations, with a strong background in value strategy, evidence development, and market access pathways. Prior to taking on his role as EU HTA lead for Cencora, he was Senior Director of Evidence Generation and Value Communications. 

Watch our latest webinars

Webinar

Achieving broad access fast! What will it take for innovative medicines to succeed?

Herbert Altmann, PhD
Cencora

Webinar

Get set for 2025: Mastering the new EU HTA statistical guidelines

Michael Hennig, PhD
Cencora

Webinar

Implications of the EU JCA on patient access and engagement

Herbert Altmann, PhD
Cencora

 

Contact us today

Pardot Form

Explore more

Stay informed about the latest insights on EU Health Technology Assessment (HTA). Explore our additional resources below to enhance your knowledge and understanding.

Additional resources

Research

The evolving landscape of PICO assessments in the EU

Kim Joline Schmidt, MSc
Cencora

Article

Preparing for change: How to navigate the EU HTA Regulation for better market access 

Herbert Altmann, PhD
Ruairi O'Donnell, PhD
Cencora

Video

Navigating the launch of ATMPs in Europe

Herbert Altmann, PhD
Cencora

Article

From PICO anxiety to PICO strategy: planning for EU HTA success

Ruairi O'Donnell, PhD
Cencora

Article

Balancing sustainability, innovation and patient access in the era of IRA and EU HTA

Casper Paardekooper 
Cencora

Article

Q&A on the latest guidelines for statistical analysis in EU HTA

Michael Hennig, PhD
Cencora

Article

Embarking on the EU HTAR realization journey: Key insights from the first of six implementing acts

HTA Quarterly
Cencora

Article

Navigating new access hurdles in Europe: A conversation with Cencora’s EU HTA Lead

Ruairi O'Donnell, PhD
Cencora

Article

Unlocking the potential of JCA in Europe: Insights from industry leaders and experts

Herbert Altmann, PhD
Cencora

Article

Does the JCA truly embrace the patients’ voice?

Herbert Altmann, PhD
Cencora

Where to meet us?

Join us at an exciting series of industry conferences including Pharma Europe, ISPOR US and ISPOR Europe to discuss how we can help you navigate the EU HTA and accelerate patient’s speed to therapy.